Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in interruptions to cancer treatment compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.13 [0.01, 2.36]
1 study · 40 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.18 [0.01, 3.56]
1 study · 40 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Oral mucositis (severe) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (severe) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.54 [0.24, 1.21]
1 study · 40 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Oral mucositis (moderate to severe) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.96 [0.80, 1.14]
1 study · 40 participants
GRADE not reported

GM-CSF vs sucralfate

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

GM-CSF showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.96 [0.8, 1.14]
1 study · 40 participants
GRADE not reported

GM-CSF vs sucralfate

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

GM-CSF showed no clear difference in oral mucositis (severe) compared with sucralfate; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.54 [0.24, 1.21]
1 study · 40 participants
GRADE not reported

Gelclair vs Sucralfate and mucaine

Mucositis severity (mild to moderate) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Gelclair showed no clear difference in mucositis severity (mild to moderate) compared with sucralfate and mucaine; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 0.50 [0.17, 1.46]
1 study · 20 participants
GRADE not reported